Cargando…

Update on tolterodine extended-release for treatment of overactive bladder

Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-relea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omotosho, Tola, Chen, Chi Chiung Grace
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818890/ https://www.ncbi.nlm.nih.gov/pubmed/24198627 http://dx.doi.org/10.2147/OAJU.S7232

Ejemplares similares

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
por: Aziminekoo, Elham, et al.
Publicado: (2014)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Tolterodine extended release is well tolerated in older subjects
por: Griebling, T L, et al.
Publicado: (2009)

Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study
por: Song, Cheryn, et al.
Publicado: (2006)

The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial
por: Xiao, Dong-dong, et al.
Publicado: (2016)

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study
por: Tang, Min, et al.
Publicado: (2023)

Dissimilar Effects of Tolterodine on Detrusor Overactivity in Awake Rats with Chemical Cystitis and Partial Bladder Outlet Obstruction
por: Jin, Long-Hu, et al.
Publicado: (2011)

Tolterodine extended release in the treatment of male oab/storage luts: a systematic review
por: Gacci, Mauro, et al.
Publicado: (2014)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Oxybutynin extended release for the management of overactive bladder: a clinical review
por: Arisco, AM, et al.
Publicado: (2009)

Update on the management of overactive bladder
por: Fontaine, Christina, et al.
Publicado: (2021)

AB078. Disease correlation and effects of pelvic floor muscle training on tolterodine based treatment for female primary overactive bladder syndrome
por: Huang, Xiao, et al.
Publicado: (2016)

Updates of Overactive Bladder in Pediatrics
por: Shim, Jisung, et al.
Publicado: (2023)

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
por: Lee, Raymond T, et al.
Publicado: (2013)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Update on the management of overactive bladder: patient considerations and adherence
por: Gomelsky, Alex, et al.
Publicado: (2010)

Comment on: update on the management of overactive bladder
por: Staskin, David
Publicado: (2022)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Updating the evidence on drugs to treat overactive bladder: a systematic review
por: Hsu, Frances C., et al.
Publicado: (2019)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
por: Hsiao, Sheng-Mou, et al.
Publicado: (2019)

Oxybutynin topical gel in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2010)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms
por: Mansfield, Kylie J., et al.
Publicado: (2022)

Pharmacologic management of overactive bladder
por: Lam, Sum, et al.
Publicado: (2007)

Overactive bladder in the vulnerable elderly
por: Wolff, Gillian F, et al.
Publicado: (2014)

Review of the epidemiology of overactive bladder
por: Eapen, Renu S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hibv7571l6epmecrkruse5bv21